PT - JOURNAL ARTICLE AU - Choi, Sylvia E. AU - Bucci, Tommaso AU - Huang, Jia-Yi AU - Yiu, Kai-Hang AU - Tsang, Christopher T. W. AU - Lau, Kui Kai AU - Hill, Andrew AU - Irving, Greg AU - Lip, Gregory Y. H. AU - Abdul-Rahim, Azmil H. TI - Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke AID - 10.1101/2024.05.21.24307724 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.21.24307724 4099 - http://medrxiv.org/content/early/2024/05/22/2024.05.21.24307724.short 4100 - http://medrxiv.org/content/early/2024/05/22/2024.05.21.24307724.full AB - Background Statins reduce recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke. We aimed to investigate the benefits of statins in patients with atrial fibrillation (AF) and recent ischaemic stroke (IS), which remain unclear.Methods This retrospective, cohort study was conducted using deidentified electronic medical records within TriNetX platform. Patients with AF and recent IS, who received statins within 28 days of their index stroke were propensity score-matched with those who did not. Patients were followed-up for 2 years. Primary outcomes were the 2-year risk of recurrent IS, all-cause mortality and the composite outcome of all-cause mortality, recurrent IS, transient ischaemic attack (TIA), and acute myocardial infarction (MI). Secondary outcomes were the 2-year risk of TIA, intracranial haemorrhage (ICH), acute MI, and hospital readmission. Cox regression analyses were used to calculate hazard ratios (HRs) with 95% confidence intervals (95%CI).Results Of 20,902 patients with AF and recent IS, 7,500 (35.9%) received statins within 28 days of their stroke and 13,402 (64.1%) did not. 11,182 patients (mean age 73.7±11.5; 5,277 (47.2%) female) remained after propensity score matching. Patients who received early statins had significantly lower risk of recurrent IS (HR: 0.45, 95%CI: 0.41–0.48, p<0.001), mortality (HR: 0.75, 95%CI: 0.66-0.84, p<0.001), the composite outcome (HR: 0.48, 95%CI: 0.45-0.52, p<0.001), TIA (HR: 0.37, 95%CI: 0.30-0.44, p<0.001), ICH (HR: 0.59, 95%CI: 0.47-0.72, p<0.001), acute MI (HR: 0.35, 95%CI: 0.30-0.42, p<0.001) and hospital readmission (HR: 0.46, 95%CI: 0.42-0.50, <0.001). Beneficial effects of early statins were evident in the elderly, different ethnicities, statin dose intensity, and AF subtypes, large vessel occlusion and embolic strokes and within the context of statin lipophilicity and optimal LDL-C levels.Conclusions Patients with AF and recent IS, who received early statins, had a lower risk of recurrent stroke, death, and other cardiovascular outcomes including ICH, compared to those who did not.Competing Interest StatementKKL received grants from Croucher Foundation, Research Fund Secretariat of the Food and Health Bureau, Innovation and Technology Bureau, Research Grants Council, Amgen, Boehringer Ingelheim, Eisai and Pfizer; and consultation fees from Amgen, Boehringer Ingelheim, Daiichi Sankyo and Sanofi, all outside the submitted work. GYHL reports Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. GYHL is a National Institute for Health and Care Research Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union?s Horizon 2020 research and innovation programme under grant agreement No 899871. AHAR reports Member of the Editorial Board of Stroke and European Stroke Journal.Clinical TrialThis study was not a clinical trial and is not required to be registered with any ICMJE-approved registryFunding StatementThis study did not receive any specific grants from public, commercial, or non-profit funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA request for access to TriNetX data can be made (https://live.trinetx.com). A data sharing agreement would be required, costs may be involved, and only de-identified information would be available.